Loss of patency by 12 months · Dialysis vascular access outcomes in AVF patients with ESKD
Omega‐3 fatty acids showed no clear difference in loss of patency: compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events: cardiovascular events · dialysis vascular access outcomes in AVG patients with ESKD
It is very uncertain whether omega‐3 fatty acids changes serious adverse events: cardiovascular events compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events: major bleeding · dialysis vascular access outcomes in AVG patients with ESKD
It is very uncertain whether omega‐3 fatty acids changes serious adverse events: major bleeding compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events: death · Dialysis vascular access outcomes in AVF patients with ESKD
Omega‐3 fatty acids showed no clear difference in serious adverse events: death compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events: hospitalisation · Dialysis vascular access outcomes in AVF patients with ESKD
Omega‐3 fatty acids showed no clear difference in serious adverse events: hospitalisation compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events: cardiovascular events · Dialysis vascular access outcomes in AVF patients with ESKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events: major bleeding · Dialysis vascular access outcomes in AVF patients with ESKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Loss of patency by 12 months · dialysis vascular access outcomes in AVG patients with ESKD
It is very uncertain whether omega‐3 fatty acids changes loss of patency by 6 months compared with placebo (very low certainty).
2 findings from 1 review
Serious adverse events: death · dialysis vascular access outcomes in AVG patients with ESKD
Omega‐3 fatty acids showed no clear difference in serious adverse events: death compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events: hospitalisation · dialysis vascular access outcomes in AVG patients with ESKD
It is very uncertain whether omega‐3 fatty acids changes serious adverse events: hospitalisation compared with placebo (very low certainty).
1 finding from 1 review
Mental state: psychotic symptoms Average total score (PANSS, higher score = worse, scale from 30‐210) Long‐term (up to 7 years) · people in the prodromal stage of psychosis
1 finding from 1 review
Behaviour: clinically important change in behaviour · people in the prodromal stage of psychosis
1 finding from 1 review
Adverse effects: neurological, extrapyramidal UKU (events) Medium‐term · people in the prodromal stage of psychosis
Group A: omega‐3 fatty acids showed no clear difference in adverse effects: neurological, extrapyramidal UKU (events) Medium‐term compared with placebo (low certainty).
1 finding from 1 review
Quality of life: clinically important change in quality of life · people in the prodromal stage of psychosis
1 finding from 1 review
Satisfaction with treatment: 1. Leaving the study early ‐ long term · people in the prodromal stage of psychosis
Group A: omega‐3 fatty acids showed no clear difference in satisfaction with treatment: leaving the study early Long‐term… compared with placebo (low certainty).
1 finding from 1 review
Prodromal symptoms: transition to psychosis Endpoint data (events) · people in the prodromal stage of psychosis
Group A: omega‐3 fatty acids may leads to lower prodromal symptoms: transition to psychosis Long‐term (events) compared with placebo (low certainty).
1 finding from 1 review
Global state: antipsychotic prescription Long‐term (events) · people in the prodromal stage of psychosis
Group A: omega‐3 fatty acids may leads to lower global state: antipsychotic prescription Long‐term (events) compared with placebo (low certainty).
1 finding from 1 review
Mortality within the longest · adults (aged 18 years or older), mechanically ventilated participants with ARDS as defined by the Berlin definition of ARDS or, for older…
Omega‐3 fatty acids and antioxidants showed no clear difference in all‐cause mortality (longest period reported) compared with placebo or standard nutrition (low certainty).
1 finding from 1 review
Duration of ICU stay · adults (aged 18 years or older), mechanically ventilated participants with ARDS as defined by the Berlin definition of ARDS or, for older…
1 finding from 1 review
Days on ventilator · adults (aged 18 years or older), mechanically ventilated participants with ARDS as defined by the Berlin definition of ARDS or, for older…
1 finding from 1 review